South Korea’s Ministry of Health and Welfare announced the signing of a memorandum of understanding (MOU) with Eli Lilly and Company on Monday at the Nine Tree Premier Hotel in Seoul. The agreement aims to advance South Korea’s pharmaceutical and biotech industries while promoting public health.
This partnership aligns with the government’s ambitious goal of propelling South Korea into the ranks of the world’s top five biotech and pharmaceutical powerhouses. It also dovetails with Lilly’s corporate mission of swiftly delivering innovative medicines to patients globally. The collaboration is designed to bolster the innovation ecosystem within South Korea’s burgeoning pharmaceutical and biotech sectors.
As part of the agreement, Lilly has committed to investing 500 million USD over the next five years. This substantial investment underscores the company’s strategic partnership with the government to enhance the capabilities and global competitiveness of South Korea’s domestic pharmaceutical and biotech industries.
The partnership will focus on fostering open innovation with local pharmaceutical and biotech firms. A key initiative includes the establishment of Lilly Gateway Labs, a global biotech venture incubation platform. Additionally, the collaboration aims to expand clinical trials in South Korea and create a research environment that meets international standards.
The scope of the partnership will gradually expand to encompass social responsibility initiatives, with a particular focus on improving healthcare access for underserved populations.
Following the MOU signing, the Ministry and Lilly will establish a joint working committee. This body will oversee ongoing efforts to strengthen the domestic pharmaceutical and biotech innovation ecosystem and expand global clinical trials in South Korea.
Health and Welfare Minister Jeong Eun-kyeong hailed the agreement as a pivotal moment for South Korea’s pharmaceutical and biotech industries. She emphasized its potential to accelerate innovation, support the development of novel drugs by promising domestic companies, and enhance their global competitiveness.
Patrik Johnson, Lilly’s International Business Lead, expressed optimism about the partnership’s potential. He hopes it will catalyze South Korea’s emergence as a global leader in the pharmaceutical and biotech sectors while improving patient care and public health through enhanced access to cutting-edge medicines.
